



Review Article

Current advances in the diagnosis and management of gastroesophageal reflux disease

Shu-Wei Liang^a, Ming-Wun Wong^{a,b}, Chih-Hsun Yi^a, Tso-Tsai Liu^a, Wei-Yi Lei^a, Jui-Sheng Hung^a, Lin Lin^a, Benjamin D. Rogers^{c,d}, Chien-Lin Chen^{a,e,*}

^aDepartment of Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan,

^bSchool of Post-Baccalaureate Chinese Medicine, Tzu Chi University, Hualien, Taiwan, ^cDivision of Gastroenterology, Hepatology and Nutrition, University of Louisville, Louisville, Kentucky, USA,

^dDivision of Gastroenterology, Washington University School of Medicine, St Louis, Missouri, USA, ^eInstitute of Medical Sciences, Tzu Chi University, Hualien, Taiwan

ABSTRACT

Gastroesophageal reflux disease (GERD) is very common and defined as troublesome symptoms owing to excessive acid reflux. The spectrum of GERD is broad, including not only erosive esophagitis and Barrett's esophagus but also nonerosive reflux disease (NERD), reflux hypersensitivity, and functional heartburn. Patients with reflux symptoms despite normal endoscopy remain common clinical presentation, can be heterogeneous overlapping with functional gastrointestinal disorders. Ambulatory esophageal pH monitoring with and without impedance helps the diagnosis of NERD. Metrics such as baseline impedance and postreflux swallow induced peristaltic wave enhance diagnostic accuracy in patients with inconclusive diagnoses. The major treatment of all manifestations of GERD is acid suppression with proton pump inhibitors, while other therapies, such as reflux-reducing agents and adjunctive medications, can be individualized where the response to traditional management is incomplete. GERD patients often need long-term treatment due to frequent relapses. Anti-reflux surgery can be effective too. Endoscopic therapies have some promising results, but long-term outcomes remain to be determined.

KEYWORDS: *Gastroesophageal reflux disease, Impedance-pH, Proton pump inhibitors*

Submission : 12-Dec-2021
Revision : 10-Jan-2022
Acceptance : 23-Feb-2022
Web Publication : 16-May-2022

INTRODUCTION

Gastroesophageal reflux disease (GERD) is the result of reflux of gastric contents entering into the esophagus in sufficient quantities to cause troublesome esophageal and/or extra-esophageal symptoms, with or without mucosal erosions and/or relevant complications (peptic stricture, esophageal ulceration, Barrett's esophagus, esophageal adenocarcinoma) [1]. The typical symptoms of GERD are recognized as heartburn and regurgitation. Extra-esophageal symptoms are broad and heterogeneous and are variably in literature as laryngeal, oropharyngeal, pulmonary, and cardiac. This range in presenting phenotypes demonstrates the profound effects of GERD on other organs, most in the proximity to the esophagus [1,2]. GERD is a common disorder with its prevalence, as defined by at least weekly heartburn and/or acid regurgitation, estimated to range from 10% to 20% in Western countries. Although similar rates are <5% in Asian countries [3], it has been demonstrated that GERD is emerging

as a leading digestive disorder in Asian countries [4]. GERD can impact on quality of life [5], and has been reported that the majority of patients with typical reflux symptoms have negative endoscopy [6]. However, some patients with esophageal erosions did not experience any symptoms [7]. In addition, atypical symptoms including cough, chest pain, and globus sensation appear to be quite prevalent in patients with GERD (20%–0%) [8]. Notably, atypical symptoms are more often reported in individuals ultimately found to have nonerosive reflux disease (NERD) [1].

Considerable developments emphasizing the importance of optimized management in patients with GERD have emerged

*Address for correspondence:

Dr. Chien-Lin Chen,
Department of Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, 707, Section 3, Chung-Yang Road, Hualien, Taiwan.
E-mail: harry.clchen@msa.hinet.net

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

How to cite this article: Liang SW, Wong MW, Yi CH, Liu TT, Lei WY, Hung JS, et al. Current advances in the diagnosis and management of gastroesophageal reflux disease. Tzu Chi Med J 2022;34(4):402-8.

Access this article online	
Quick Response Code: 	Website: www.tcmjmed.com
	DOI: 10.4103/tcmj.tcmj_323_21

in recent years. It has been observed that the absence of erosive esophagitis is common in community-based practices [9]. In addition, those patients have a less favorable response to proton pump inhibitors (PPIs) as compared to those having erosive esophagitis [10]. The Rome IV Committee recently outlined the classification scheme for functional esophageal disorders including reflux hypersensitivity and functional heartburn, based on typical GERD symptoms with normal acid exposure time in individuals considered not responsive to PPIs [11].

PATHOPHYSIOLOGY

Impaired esophagogastric junction barrier

An ineffective esophagogastric junction (EGJ) barrier is consistently present in GERD, often combined with morphological abnormality (hiatus hernia). Transient lower esophageal sphincter relaxation (TLESR) is a physiological response to gastric distension, and excessive reflux during TLESRs is the most common EGJ event seen in patients with GERD [12]. An intact EGJ should be composed of a lower esophageal sphincter and diaphragmatic crura. An impaired EGJ barrier can be hypotensive lower esophageal sphincter that can be overcome by increased intra-abdominal pressure or disrupted and separated lower esophageal sphincter and diaphragmatic crura (hiatus hernia), or both. In patients with hiatus hernia, the resting tone of the intrinsic lower esophageal sphincter is typically hypotensive, with esophageal reflux burden higher under these circumstances than with either abnormality alone [13]. Consequently, both types of EGJ abnormalities can coexist and both can result in abnormal reflux burden.

Esophageal hypomotility

When a reflux episode occurs, the refluxate can be cleared by a combination of a secondary peristaltic contraction and a primary post-reflux swallow-induced peristaltic contraction that also brings saliva to neutralize esophageal mucosal acidification [14]. In many patients with GERD, esophageal motor function is intact and normal [15]; however, hypomotility can contribute to delayed esophageal clearance and increases the likelihood of esophagitis [16]. More severe GERD was found in patients with more ineffective swallows [17].

Refluxate and acid burden

The gastric acid forms a layer of acid floating on the top of ingested food just below EGJ, the acid pocket [18]. In patients with hiatus hernia, the acid pocket can move into the distal esophagus, causing prolonged acid exposure in the distal esophagus [19]. Delayed gastric emptying and acid hypersecretory states, such as in gastrin-secreting tumors (gastrinomas), are additional predisposing factors that contribute to esophageal reflux burden [12]. Acid and other components of the refluxate (pepsin, bile acid) can participate in mucosal damage and complications including Barrett's esophagus [20]. Patients with reflux hypersensitivity or functional heartburn report similar symptoms to typical GERD, potentially through peripheral and central mechanisms, despite reflux burden being regarded as physiological level [11,21].

Psychiatric comorbidity and hypervigilance

Psychosocial comorbidities can influence the symptom presentation and therapeutic response of GERD [22]. Esophageal hypervigilance is a neurological process of both cognition and mood, such as increased attention to esophageal sensations or stress about GERD symptoms [22]. Recently, the esophageal hypervigilance and anxiety scale (EHAS) has been proposed as a validated cognitive-affective evaluation of centrally mediated esophageal symptom perception, and positively correlates with symptom severity of GERD, but is not influenced by 24-hour impedance-pH metrics including acid reflux burden, number of reflux events or mucosal integrity [23,24]. Thus, EHAS is a measure of patient perception of symptoms, it provides insights into psychological modifiers of symptom perception, and could be an important metric to assess outcome of GERD therapy independent of the modality [24].

DIAGNOSTIC TESTING FOR GASTROESOPHAGEAL REFLUX DISEASE

A diagnosis of GERD is often clinically made based on typical symptoms and the response to PPIs [25]. There are generally two main approaches for the diagnostic test: Endoscopic confirmation of esophageal mucosal injury, and catheter detection of pathologic acid exposure by prolonged ambulatory monitoring with pH or combined pH-impedance [26].

High resolution manometry

Although high-resolution manometry (HRM) is not used for the diagnosis of GERD itself, patients with GERD often have abnormal esophageal motility [17]. A recent study utilizing HRM revealed that acid reflux burden is more profound in patients with absent primary peristalsis, as well as in patients lacking a secondary peristaltic response to esophageal air distension [27]. HRM is recommended to exclude diagnosis other than GERD in patients with esophageal symptoms and failed PPI treatment. Achalasia can present with typical reflux symptoms together with dysphagia [28].

Endoscopy

The Los Angeles (LA) classification is the most common grading system of reflux-related esophageal injury, including mild (grades A and B) and severe (grades C and D) esophagitis [29]. However, about two-thirds of untreated patients with heartburn and regurgitation do not have erosive esophagitis, absence of esophagitis does not rule out GERD [30]. Since endoscopists have significant variability in determining mild erosive esophagitis [31], pH-metry test is recommended to document GERD in patients with mild erosive esophagitis before anti-reflux surgery [32]. Furthermore, biopsies should be done if eosinophilic esophagitis or Barrett's esophagus is suspected.

Reflux monitoring

The main purpose of reflux monitoring is to document whether a pathologic level of reflux is present. Reflux monitoring can record the correlation of symptom and

reflux. Reflux monitoring is performed either by pH-metry or pH-metry combined with impedance.

Catheter-based and wireless pH monitoring

Ambulatory pH monitoring records in the distal esophagus. Transnasal catheter record over a 24-h period and wireless pH capsule can record up to 96 h. Parameters derived include acid exposure time (time percentage of esophageal pH <4 over the total time), reflux episode number, prolonged reflux episode number (reflux episode >5 min), and longest reflux episode. All these parameters can be combined in a composite score, DeMeester score [33]. A positive pH test establishes a diagnosis of GERD when even the endoscopy does not reveal evidence of erosive esophagitis. A positive pH test can also confirm or exclude GERD in patients who do not have adequate symptom control with a PPI. An abnormal 24-hour pH score was associated with successful outcome of laparoscopic fundoplication (odds ratio of 5.4; 95% confidence interval, 1.9–15.3) [34]. Wireless pH monitoring is more tolerated for prolonged recording, and has similarly accuracy compared with catheter-based pH monitoring [35]. The definitions of NERD, acid hypersensitive esophagus and functional heartburn rely on the interpretations of the temporal relationships between symptoms and reflux events assessed with symptom index (SI), symptom association probability (SAP) or both. SI is a simple, easy to determine and understand parameter, and describes the proportion of symptoms that are reflux-related. SAP describes the probability that the observed relation between symptoms and reflux does not occur by chance. The analysis of symptom-reflux association is still clinically helpful to better identify those patients with symptoms that are related to acid reflux.

Impedance-pH monitoring

Standard pH monitoring allows measuring acid reflux by detecting pH drops in the distal esophagus. However, when gastric acid was buffered in the postprandial period or suppressed by a PPI, refluxate can become pH >4, which is weakly acidic reflux or nonacid reflux. In addition to pH monitoring, impedance-pH monitoring characterizes fluid and gas as well as detects the movement of fluid and gas. Combined pH and impedance recording technology enable the detection of acid and nonacid reflux episodes. This technology also allows for better characterization of the proximal extent of reflux, postreflux clearance, reflux episodes, including not only acidity (acid, nonacid) but also composition (air, liquid, or mixed). Therefore, it is currently considered to be the most accurate and detailed method to assess gastroesophageal reflux [36]. Adding impedance to pH monitoring improves the diagnostic yield and allows better symptom analysis. Several studies have evaluated the use of 24-h pH-impedance monitoring in refractory patients taking PPIs twice daily, and the results can be summarized as follows: 50%–60% of patients do not have symptoms that can be associated with GERD, 30%–40% have symptoms associated with nonacid reflux, and approximately 10% have symptoms associated with acid reflux [37-39]. It has been suggested that patients with refractory heartburn and negative symptom association indices during pH-impedance monitoring performed on therapy should probably be considered as having functional heartburn [40].

Novel impedance-based parameters

Two novel metrics extracted from pH-impedance studies, mean nocturnal baseline impedance (MNBI) and the postreflux swallow-induced peristaltic wave (PSPW) index, have augmented the diagnostic value of pH-impedance monitoring [41,42].

Low baseline mucosal impedance (MI) values, traditionally taken during three separate quiet nighttime periods, have been associated with abnormal mucosal integrity, elevated acid exposure time, and reflux symptoms [43-45]. Further, low MNBI independently predicts response to antireflux therapy [46], especially when the acid exposure time is borderline or inconclusive [47].

The presence of refluxate in the distal esophagus triggers primary peristalsis, allowing delivery of salivary bicarbonate to reverse esophageal mucosal acidification. This can be identified on pH-impedance tracings as a swallow occurring within 30 s of a reflux episode (PSPW), and the proportion of reflux episodes followed by PSPW is termed the PSPW index [48]. Lower PSPW index was reported to segregate GERD patients, especially those with a lack of PPI response, from healthy individuals [48,49].

New techniques

Esophageal mucosal integrity can be measured during esophageal contraction on HRM with impedance and is termed contractile segment impedance (CSI). This method has the added benefits of being convenient and faster [50]. In addition, CSI is expected to have better mucosal contact with the impedance sensor because measurements are obtained during esophageal smooth muscle contraction [50]. A recent study has demonstrated that CSI identifies GERD with equivalent efficacy to MNBI [51].

Esophageal mucosal integrity can also be assessed through a MI device comprised of two radial sensors mounted on a 10 cm balloon that is inflated to insure optimal contact with a long segment of esophageal mucosa. Initial results are promising that MI values correlate with esophageal mucosal inflammation, differentiating erosive and nonerosive GERD from eosinophilic esophagitis and normal patients with better specificity (95% vs. 64%) and positive predictive value (96% vs. 40%) compared with pH monitoring [52-55].

Modern diagnosis of gastroesophageal reflux disease: The Lyon consensus

The recent Lyon consensus delineates parameters on ambulatory reflux monitoring that categorically establish and rule out the presence of GERD [56]. In particular, conclusive evidence for reflux on esophageal testing includes severe erosive esophagitis (LA grades C and D), long-segment Barrett's esophagus, or peptic strictures on endoscopy or distal esophageal acid exposure time >6% on ambulatory pH or multichannel intraluminal impedance-pH monitoring. On the other hand, acid exposure time between 4% and 6% is regarded as inconclusive for GERD. In these patients, adjunctive tests, including HRM and novel impedance-pH metrics (MNBI, PSPW and MI), which may either confirm or reject the diagnosis of GERD. The advantages and disadvantages of diagnostic methods for GERD are summarized in Table 1.

Table 1: Advantages and disadvantages of diagnostic methods for gastroesophageal reflux disease

Methods	Advantages	Disadvantages
GERD questionnaires	Convenience for primary care physicians	Unable to discriminate pathologic reflux from functional heartburn
PPI test	Usefulness in primary care for patients without alarm symptoms	Low specificity: 24%–65%
Endoscopy	Diagnosis of erosive esophagitis, Barrett's esophagus, and eosinophilic esophagitis	Poor sensitivity; 70% of patients have normal mucosa
Wireless pH-metry	Prolonged monitoring to overcome day-to-day variability; better patients' tolerance	Expensive and endoscopy-required
pH-impedance	Detection of acid/nonacid reflux, aerophagia and supragastric belching	Day-to-day variability and unpleasant for patients
MNBI, CSI and PSPW	Augmentation for distinction between patients with GERD versus functional heartburn	Requires manometry and/or catheter-based pH-impedance; time-consuming manual calculations
Mucosal impedance	Direct measurement of mucosal integrity all along esophageal axis and radial distribution to identify NERD, erosive esophagitis, Barrett's esophagus, and eosinophilic esophagitis	Undergoing validation studies and endoscopy-required

GERD: Gastroesophageal reflux disease, PPI: Proton pump inhibitor, MNBI: Mean nocturnal baseline impedance, CSI: Contractile segment impedance, PSPW: Postreflux swallow-induced peristaltic wave, NERD: Nonerosive reflux disease

MANAGEMENTS

After confirmation of GERD, the treatment commonly starts with PPI therapy and complementary lifestyle measures for patients without alarm symptoms. Optimizing PPI therapy and discussing appropriate administration are critical factors in ensuring compliance and increasing dosage to twice daily can be considered in selective patients with persistent symptoms. Patients with continued symptoms can be evaluated with tests of esophageal physiology, to better determine their disease phenotype and optimize treatment. Primary care providers should be cautious to inquire origin of symptom generation to be reflux or nonreflux mechanism when symptoms respond poorly to optimal PPI therapy.

Proton pump inhibitors

Short-term PPI therapy heals esophagitis in 72%–83% of patients (compared with 18%–20% for placebo)[57] but resolves heartburn in only 56%–77% of patients with esophagitis (with 4–12 weeks of therapy) [10]. PPIs maintain healing of erosive esophagitis in 93% of patients (compared with 29% of patients for placebo) [58]. The standard dose of PPIs resolves heartburn in only 37%–61% of patients without erosive esophagitis or with uninvestigated heartburn [59]. Patients with a poor or incomplete treatment response to PPIs are recommended to have esophageal pH monitoring to confirm the evidence of pathological acid reflux as a cause of symptoms [60]. Response rates are lower in patients with atypical symptoms of GERD, indicating potential differences in mechanisms of pathogenesis. Current updates of personalized managements are summarized in the Figure 1.

Potassium-competitive acid blockers

Potassium-competitive acid blockers (P-CABs) competitively and reversibly act at the potassium-binding site of the proton pump. Compared to PPIs, P-CABs accumulate more in the parietal cells' canaliculi. In addition, P-CABs bind to both the active and inactive forms of the proton pump resulting in a faster and longer duration of the anti-secretory effect than PPIs [61,62]. Overall, P-CABs were noninferior to PPIs in healing erosive esophagitis and maintaining healed erosive esophagitis. P-CABs have demonstrated better and earlier healing of advanced erosive esophagitis (grade C or D) than PPIs [63-66].




Figure 1: Individualized management of GERD according to precise phenotyping. NERD, non-erosive reflux disease; PPI: Proton pump inhibitor; P-CAB: Potassium-competitive acid blocker, GERD: Gastroesophageal reflux disease, NERD: Nonerosive reflux disease

H2 receptor antagonists

H2-receptor antagonists (H2RAs) competitively inhibit histamine receptors in the gastric parietal cell. H2RAs allow esophagitis healing in 41% of patients as compared with 18%–20% placebo [67]. H2RAs relieve heartburn in 48%–56% after 4–12 weeks of treatment [68]. H2RAs can be used as part of an alternative for patients with uncomplicated GERD following PPI-induced remission of symptoms. This step-down therapy is generally only recommended for patients without erosive esophagitis or BE.

Reflux-reducing agents

Baclofen, a gamma-aminobutyric acid B receptor agonist reduces TLESRs and reflux episodes in healthy volunteers as well as patients with GERD [69]. However, central side effects from baclofen (dizziness and somnolence) may limit its utility, and data regarding long-term symptom benefit are conflicting.

Adjunct medications

Antacids are basic aluminum, calcium, or magnesium compounds and are used to control intermittent esophageal symptoms, especially heartburn. Their advantage is fast onset and fast relief of symptoms. Antacids do not maintain longer symptoms relief, help erosive esophagitis healing,

or prevent GERD complications, like Barrett's esophagus or erosive esophagitis [70]. Alginates form a raft and create a physical barrier against reflux in the acid pocket [71]. When alginates are combined with antacids, combination is more efficacious at relieving heartburn and acid reflux than antacids alone [72]. Prokinetic agents (metoclopramide, domperidone, and mosapride) are potentially useful for reducing symptoms of GERD by increasing lower esophageal sphincter basal tone, increasing esophageal acid clearance, and accelerating gastric emptying. However, a meta-analysis of randomized studies found only modest reductions in symptom scores when prokinetics were added to PPI therapy [73].

Nonpharmacological management

Anti-reflux surgery as surgical fundoplication can reduce all types of reflux, including weakly acidic and nonacid. Surgical fundoplication is at least as effective as continued PPI therapy and, in some studies, was even superior to pharmacological therapy in controlling GERD symptoms [74-76]. Criteria of candidates for surgical fundoplication include patients with large hiatal hernia, regurgitation as the predominant symptom, abnormal acid exposure time, poor healing of erosive esophagitis despite maximum PPI dose, and those with symptoms that correlate with gastro-esophageal reflux despite maximum PPI dose [77,78].

Endoscopic anti-reflux procedures are considered as an alternative for anti-reflux surgery and chronic PPI treatment. Initially, endoscopic fundoplication and radiofrequency energy delivery are two endoscopic procedures for the treatment of GERD [79]. Recently, antireflux mucosectomy and antireflux mucosal ablation are novel endoscopic intervention to induce cardiac scar formation that reduces the opening of the EGJ through the healing process [80-82]. Endoscopic therapies for GERD have demonstrated short-term effectiveness such as improved health-related quality of life, reflux symptom severity, acid exposure time, and reduced PPI use, but long-term outcomes remain unclear [83-86]. Of note, criteria of candidates for endoscopic procedures include typical GERD symptoms (heartburn and/or regurgitation), low-grade erosive esophagitis (grade A or B) or NERD, negative of major motility disorders, hiatal hernia <3 cm in size, and complete or partial response to PPI treatment [87].

CONCLUSIONS

The pathogenesis of GERD involves impaired EGJ barrier, esophageal hypomotility, refluxate and acid burden, psychiatric comorbidity, and hypervigilance. Acid-inhibition therapy is the mainstay of medical treatment for GERD. Recent advances in diagnostic testing for GERD have shed light on tailored management.

Financial support and sponsorship

Nil.

Conflicts of interest

Dr. Chien-Lin Chen, an editorial board member at *Tzu Chi Medical Journal*, had no role in the peer review process of or decision to publish this article. The other authors declared no conflicts of interest in writing this paper.

REFERENCES

- Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: A global evidence-based consensus. *Am J Gastroenterol* 2006;101:1900-20.
- Naik RD, Vaezi MF. Extra-esophageal gastroesophageal reflux disease and asthma: Understanding this interplay. *Expert Rev Gastroenterol Hepatol* 2015;9:969-82.
- Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. *Lancet* 2006;367:2086-100.
- Fock KM, Talley NJ, Fass R, Goh KL, Katelaris P, Hunt R, et al. Asia-Pacific consensus on the management of gastroesophageal reflux disease: Update. *J Gastroenterol Hepatol* 2008;23:8-22.
- Wiklund I. Review of the quality of life and burden of illness in gastroesophageal reflux disease. *Dig Dis* 2004;22:108-14.
- El-Serag HB. Epidemiology of non-erosive reflux disease. *Digestion* 2008;78 (Suppl 1):6-10.
- Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: A Kalixanda study report. *Scand J Gastroenterol* 2005;40:275-85.
- Yi CH, Liu TT, Chen CL. Atypical symptoms in patients with gastroesophageal reflux disease. *J Neurogastroenterol Motil* 2012;18:278-83.
- Carlsson R, Dent J, Watts R, Riley S, Sheikh R, Hatlebakk J, et al. Gastro-oesophageal reflux disease in primary care: An international study of different treatment strategies with omeprazole. International GORD Study Group. *Eur J Gastroenterol Hepatol* 1998;10:119-24.
- Dean BB, Gano AD Jr., Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. *Clin Gastroenterol Hepatol* 2004;2:656-64.
- Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Functional Esophageal Disorders. *Gastroenterology* 2016;S0016-5085:00178-5.
- Bredenoord AJ, Pandolfino JE, Smout AJ. Gastro-oesophageal reflux disease. *Lancet* 2013;381:1933-42.
- Sloan S, Kahrilas PJ. Impairment of esophageal emptying with hiatal hernia. *Gastroenterology* 1991;100:596-605.
- Helm JF, Dodds WJ, Pelc LR, Palmer DW, Hogan WJ, Teeter BC. Effect of esophageal emptying and saliva on clearance of acid from the esophagus. *N Engl J Med* 1984;310:284-8.
- Chan WW, Haroian LR, Gyawali CP. Value of preoperative esophageal function studies before laparoscopic antireflux surgery. *Surg Endosc* 2011;25:2943-9.
- Daum C, Sweis R, Kaufman E, Fuelleman A, Anggiansah A, Fried M, et al. Failure to respond to physiologic challenge characterizes esophageal motility in erosive gastro-esophageal reflux disease. *Neurogastroenterol Motil* 2011;23:517-e200.
- Savarino E, Gemignani L, Pohl D, Zentilin P, Dulbecco P, Assandri L, et al. Oesophageal motility and bolus transit abnormalities increase in parallel with the severity of gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 2011;34:476-86.
- Beaumont H, Bennink RJ, de Jong J, Boeckxstaens GE. The position of the acid pocket as a major risk factor for acidic reflux in healthy subjects and patients with GORD. *Gut* 2010;59:441-51.
- Kahrilas PJ, McColl K, Fox M, O'Rourke L, Sifrim D, Smout AJ, et al. The acid pocket: A target for treatment in reflux disease? *Am J Gastroenterol* 2013;108:1058-64.
- Koek GH, Sifrim D, Lerut T, Janssens J, Tack J. Multivariate analysis of the association of acid and duodeno-gastro-oesophageal reflux exposure with the presence of oesophagitis, the severity of oesophagitis and Barrett's oesophagus. *Gut* 2008;57:1056-64.
- Woodland P, Aktar R, Mthunzi E, Lee C, Peiris M, Preston SL, et al.

- Distinct afferent innervation patterns within the human proximal and distal esophageal mucosa. *Am J Physiol Gastrointest Liver Physiol* 2015;308:G525-31.
22. Kessing BF, Bredenoord AJ, Saleh CM, Smout AJ. Effects of anxiety and depression in patients with gastroesophageal reflux disease. *Clin Gastroenterol Hepatol* 2015;13:1089-95.e1.
 23. Taft TH, Triggs JR, Carlson DA, Guadagnoli L, Tomasino KN, Keefer L, et al. Validation of the oesophageal hypervigilance and anxiety scale for chronic oesophageal disease. *Aliment Pharmacol Ther* 2018;47:1270-7.
 24. Wong MW, Liu TT, Yi CH, Lei WY, Hung JS, Cock C, et al. Oesophageal hypervigilance and visceral anxiety relate to reflux symptom severity and psychological distress but not to acid reflux parameters. *Aliment Pharmacol Ther* 2021;54:923-30.
 25. Klauser AG, Schindlbeck NE, Müller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. *Lancet* 1990;335:205-8.
 26. Vaezi MF, Sifrim D. Assessing old and new diagnostic tests for gastroesophageal reflux disease. *Gastroenterology* 2018;154:289-301.
 27. Wong MW, Hung JS, Liu TT, Yi CH, Lei WY, Liang SW, et al. Esophageal acid burden in reflux patients with normal endoscopy: Does esophageal peristalsis matter? *J Formos Med Assoc* 2022;121:388-94.
 28. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. *Am J Gastroenterol* 2013;108:308-28.
 29. Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, et al. Endoscopic assessment of oesophagitis: Clinical and functional correlates and further validation of the Los Angeles classification. *Gut* 1999;45:172-80.
 30. Johnsson F, Joelsson B, Gudmundsson K, Greiff L. Symptoms and endoscopic findings in the diagnosis of gastroesophageal reflux disease. *Scand J Gastroenterol* 1987;22:714-8.
 31. Vaezi MF, Pandolfino JE, Vela MF, Shaheen NJ. White paper AGA: Optimal strategies to define and diagnose gastroesophageal reflux disease. *Clin Gastroenterol Hepatol* 2017;15:1162-72.
 32. Jobe BA, Richter JE, Hoppo T, Peters JH, Bell R, Dengler WC, et al. Preoperative diagnostic workup before antireflux surgery: An evidence and experience-based consensus of the Esophageal Diagnostic Advisory Panel. *J Am Coll Surg* 2013;217:586-97.
 33. Johnson LF, Demeester TR. Twenty-four-hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux. *Am J Gastroenterol* 1974;62:325-32.
 34. Campos GM, Peters JH, DeMeester TR, Oberg S, Crookes PF, Tan S, et al. Multivariate analysis of factors predicting outcome after laparoscopic Nissen fundoplication. *J Gastrointest Surg* 1999;3:292-300.
 35. Pandolfino JE, Zhang Q, Schreiner MA, Ghosh S, Roth MP, Kahrilas PJ. Acid reflux event detection using the Bravo wireless versus the Slimline catheter pH systems: Why are the numbers so different? *Gut* 2005;54:1687-92.
 36. Sifrim D, Castell D, Dent J, Kahrilas PJ. Gastro-oesophageal reflux monitoring: Review and consensus report on detection and definitions of acid, non-acid, and gas reflux. *Gut* 2004;53:1024-31.
 37. Hemmink GJ, Bredenoord AJ, Weusten BL, Monkelbaan JF, Timmer R, Smout AJ. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'On' or 'off' proton pump inhibitor? *Am J Gastroenterol* 2008;103:2446-53.
 38. Mainie I, Tutuian R, Shay S, Vela M, Zhang X, Sifrim D, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: A multicentre study using combined ambulatory impedance-pH monitoring. *Gut* 2006;55:1398-402.
 39. Zerbib F, Roman S, Ropert A, des Varannes SB, Poudoux P, Chaput U, et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: A study in patients off and on therapy. *Am J Gastroenterol* 2006;101:1956-63.
 40. Frazzoni M, Conigliaro R, Mirante VG, Melotti G. The added value of quantitative analysis of on-therapy impedance-pH parameters in distinguishing refractory non-erosive reflux disease from functional heartburn. *Neurogastroenterol Motil* 2012;24:141-6, e87.
 41. Frazzoni M, Bertani H, Manta R, Mirante VG, Frazzoni L, Conigliaro R, et al. Impairment of chemical clearance is relevant to the pathogenesis of refractory reflux oesophagitis. *Dig Liver Dis* 2014;46:596-602.
 42. Martinucci I, de Bortoli N, Savarino E, Piaggi P, Bellini M, Antonelli A, et al. Esophageal baseline impedance levels in patients with pathophysiological characteristics of functional heartburn. *Neurogastroenterol Motil* 2014;26:546-55.
 43. Kandulski A, Weigt J, Caro C, Jechorek D, Wex T, Malfertheiner P. Esophageal intraluminal baseline impedance differentiates gastroesophageal reflux disease from functional heartburn. *Clin Gastroenterol Hepatol* 2015;13:1075-81.
 44. Woodland P, Al-Zinaty M, Yazaki E, Sifrim D. *In vivo* evaluation of acid-induced changes in oesophageal mucosa integrity and sensitivity in non-erosive reflux disease. *Gut* 2013;62:1256-61.
 45. Zhong C, Duan L, Wang K, Xu Z, Ge Y, Yang C, et al. Esophageal intraluminal baseline impedance is associated with severity of acid reflux and epithelial structural abnormalities in patients with gastroesophageal reflux disease. *J Gastroenterol* 2013;48:601-10.
 46. Patel A, Wang D, Sainani N, Sayuk GS, Gyawali CP. Distal mean nocturnal baseline impedance on pH-impedance monitoring predicts reflux burden and symptomatic outcome in gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 2016;44:890-8.
 47. Rengarajan A, Savarino E, Della Coletta M, Ghisa M, Patel A, Gyawali CP. Mean nocturnal baseline impedance correlates with symptom outcome when acid exposure time is inconclusive on esophageal reflux monitoring. *Clin Gastroenterol Hepatol* 2020;18:589-95.
 48. Frazzoni M, Savarino E, de Bortoli N, Martinucci I, Furnari M, Frazzoni L, et al. Analyses of the post-reflux swallow-induced peristaltic wave index and nocturnal baseline impedance parameters increase the diagnostic yield of impedance-pH monitoring of patients with reflux disease. *Clin Gastroenterol Hepatol* 2016;14:40-6.
 49. Frazzoni L, Frazzoni M, de Bortoli N, Tolone S, Furnari M, Martinucci I, et al. Postreflux swallow-induced peristaltic wave index and nocturnal baseline impedance can link PPI-responsive heartburn to reflux better than acid exposure time. *Neurogastroenterol Motil* 2017;29. [doi: 10.1111/nmo.13116].
 50. Mei L, Babaei A. Contractile Segment Impedance (CSI) during high-resolution impedance manometry highly correlates with intraluminal Baseline Impedance (BI), and is inversely related to esophageal acid exposure. *Gastroenterology* 2018;154:S85-6.
 51. Wong MW, Liu TT, Yi CH, Lei WY, Hung JS, Omari T, et al. Analysis of contractile segment impedance during straight leg raise maneuver using high-resolution impedance manometry increases diagnostic yield in reflux disease. *Neurogastroenterol Motil* 2022;34:e14135.
 52. Ates F, Yuksel ES, Higginbotham T, Slaughter JC, Mabary J, Kavitt RT, et al. Mucosal impedance discriminates GERD from non-GERD conditions. *Gastroenterology* 2015;148:334-43.
 53. Katzka DA, Ravi K, Geno DM, Smyrk TC, Iyer PG, Alexander JA, et al. Endoscopic mucosal impedance measurements correlate with eosinophilia and dilation of intercellular spaces in patients with eosinophilic esophagitis. *Clin Gastroenterol Hepatol* 2015;13:1242-8.e1.
 54. Lei WY, Vaezi MF, Naik RD, Chen CL. Mucosal impedance testing: A new diagnostic testing in gastroesophageal reflux disease. *J Formos Med Assoc* 2020;119:1575-80.
 55. Saritas Yuksel E, Higginbotham T, Slaughter JC, Mabary J, Kavitt RT, Garrett CG, et al. Use of direct, endoscopic-guided measurements of mucosal impedance in diagnosis of gastroesophageal reflux disease. *Clin Gastroenterol Hepatol* 2012;10:1110-6.
 56. Gyawali CP, Kahrilas PJ, Savarino E, Zerbib F, Mion F, Smout AJPM, et al. Modern diagnosis of GERD: The Lyon Consensus. *Gut* 2018;67:1351-62.

57. Weijenberg PW, Cremonini F, Smout AJ, Bredenoord AJ. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: A meta-analysis. *Neurogastroenterol Motil* 2012;24:747-57, e350.
58. Johnson DA, Benjamin SB, Wakil NB, Goldstein JL, Lamet M, Whipple J, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: A randomized, double-blind, placebo-controlled study of efficacy and safety. *Am J Gastroenterol* 2001;96:27-34.
59. Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. *Cochrane Database Syst Rev* 2013;2013:CD002095.
60. Roman S, Gyawali CP, Savarino E, Yadlapati R, Zerbib F, Wu J, et al. Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: Update of the Porto consensus and recommendations from an international consensus group. *Neurogastroenterol Motil* 2017;29:1-15.
61. Andersson K, Carlsson E. Potassium-competitive acid blockade: A new therapeutic strategy in acid-related diseases. *Pharmacol Ther* 2005;108:294-307.
62. Beil W, Hackbarth I, Sewing KF. Mechanism of gastric antisecretory effect of SCH 28080. *Br J Pharmacol* 1986;88:19-23.
63. Ashida K, Iwakiri K, Hiramatsu N, Sakurai Y, Hori T, Kudou K, et al. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole. *World J Gastroenterol* 2018;24:1550-61.
64. Ashida K, Sakurai Y, Hori T, Kudou K, Nishimura A, Hiramatsu N, et al. Randomised clinical trial: Vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. *Aliment Pharmacol Ther* 2016;43:240-51.
65. Ashida K, Sakurai Y, Nishimura A, Kudou K, Hiramatsu N, Umegaki E, et al. Randomised clinical trial: A dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. *Aliment Pharmacol Ther* 2015;42:685-95.
66. Xiao Y, Zhang S, Dai N, Fei G, Goh KL, Chun HJ, et al. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. *Gut* 2020;69:224-30.
67. Khan M, Santana J, Donnellan C, Preston C, Moayyedi P. Medical treatments in the short term management of reflux oesophagitis. *Cochrane Database Syst Rev* 2007;2:CD003244.
68. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. *Gastroenterology* 1997;112:1798-810.
69. Vela MF, Tutuian R, Katz PO, Castell DO. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. *Aliment Pharmacol Ther* 2003;17:243-51.
70. Weberg R, Berstad A. Symptomatic effect of a low-dose antacid regimen in reflux oesophagitis. *Scand J Gastroenterol* 1989;24:401-6.
71. Rohof WO, Bennink RJ, Smout AJ, Thomas E, Boeckxstaens GE. An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. *Clin Gastroenterol Hepatol* 2013;11:1585-91.
72. van Hagen P, de Jonge R, van Berge Henegouwen MI, Hötte GJ, van der Stok EP, Lindemans J, et al. Vitamin B12 deficiency after esophagectomy with gastric tube reconstruction for esophageal cancer. *Dis Esophagus* 2017;30:1-8.
73. Ren LH, Chen WX, Qian LJ, Li S, Gu M, Shi RH. Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: A meta-analysis. *World J Gastroenterol* 2014;20:2412-9.
74. Galmiche JP, Hatlebakk J, Attwood S, Ell C, Fiocca R, Eklund S, et al. Laparoscopic antireflux surgery vs. esomeprazole treatment for chronic GERD: The LOTUS randomized clinical trial. *JAMA* 2011;305:1969-77.
75. Garg SK, Gurusamy KS. Laparoscopic fundoplication surgery versus medical management for gastro-oesophageal reflux disease (GORD) in adults. *Cochrane Database Syst Rev* 2015;2015:CD003243.
76. Lundell L, Miettinen P, Myrvold HE, Pedersen SA, Liedman B, Hatlebakk JG, et al. Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. *J Am Coll Surg* 2001;192:172-9.
77. Gyawali CP, Fass R. Management of gastroesophageal reflux disease. *Gastroenterology* 2018;154:302-18.
78. Sandhu DS, Fass R. Current trends in the management of gastroesophageal reflux disease. *Gut Liver* 2018;12:7-16.
79. Maradey-Romero C, Kale H, Fass R. Nonmedical therapeutic strategies for nonerosive reflux disease. *J Clin Gastroenterol* 2014;48:584-9.
80. Inoue H, Ito H, Ikeda H, Sato C, Sato H, Phalansitthepha C, et al. Anti-reflux mucosectomy for gastroesophageal reflux disease in the absence of hiatus hernia: A pilot study. *Ann Gastroenterol* 2014;27:346-51.
81. Inoue H, Tanabe M, de Santiago ER, Abad MR, Shimamura Y, Fujiyoshi Y, et al. Anti-reflux mucosal ablation (ARMA) as a new treatment for gastroesophageal reflux refractory to proton pump inhibitors: A pilot study. *Endosc Int Open* 2020;8:E133-8.
82. Hernández Mondragón OV, Zamarripa Mottú RA, García Contreras LF, Gutiérrez Aguilar RA, Solórzano Pineda OM, Blanco Velasco G, et al. Clinical feasibility of a new antireflux ablation therapy on gastroesophageal reflux disease (with video). *Gastrointest Endosc* 2020;92:1190-201.
83. Fass R, Cahn F, Scotti DJ, Gregory DA. Systematic review and meta-analysis of controlled and prospective cohort efficacy studies of endoscopic radiofrequency for treatment of gastroesophageal reflux disease. *Surg Endosc* 2017;31:4865-82.
84. Richter JE, Kumar A, Lipka S, Miladinovic B, Velanovich V. Efficacy of laparoscopic nissen fundoplication vs. transoral incisionless fundoplication or proton pump inhibitors in patients with gastroesophageal reflux disease: A systematic review and network meta-analysis. *Gastroenterology* 2018;154:1298-308.e7.
85. Testoni PA, Testoni S, Mazzoleni G, Pantaleo G, Ciona MB, Distefano G, et al. Transoral incisionless fundoplication with an ultrasonic surgical endostapler for the treatment of gastroesophageal reflux disease: 12-month outcomes. *Endoscopy* 2020;52:469-73.
86. Rodríguez de Santiago E, Sanchez-Vegazo CT, Peñas B, Shimamura Y, Tanabe M, Álvarez-Díaz N, et al. Antireflux mucosectomy (ARMS) and antireflux mucosal ablation (ARMA) for gastroesophageal reflux disease: A systematic review and meta-analysis. *Endosc Int Open* 2021;9:E1740-51.
87. Fass R. Endoscopic approaches for the treatment of gastroesophageal reflux disease. *Gastroenterol Hepatol (N Y)* 2019;15:555-7.